Quadrant Capital Group LLC Buys 2,882 Shares of Becton, Dickinson and Company $BDX

Quadrant Capital Group LLC lifted its position in Becton, Dickinson and Company (NYSE:BDX) by 86.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,233 shares of the medical instruments supplier’s stock after acquiring an additional 2,882 shares during the period. Quadrant Capital Group LLC’s holdings in Becton, Dickinson and Company were worth $1,074,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Saudi Central Bank acquired a new stake in Becton, Dickinson and Company in the first quarter worth $26,000. Bell Investment Advisors Inc raised its stake in Becton, Dickinson and Company by 474.1% during the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 128 shares during the period. Kelly Lawrence W & Associates Inc. CA bought a new position in Becton, Dickinson and Company during the first quarter worth about $31,000. Bank of Jackson Hole Trust grew its stake in Becton, Dickinson and Company by 85.6% in the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after acquiring an additional 95 shares during the period. Finally, WPG Advisers LLC bought a new stake in shares of Becton, Dickinson and Company in the first quarter worth about $36,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on BDX. Piper Sandler cut their price objective on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a report on Friday, November 7th. Wells Fargo & Company lifted their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Morgan Stanley increased their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Finally, Stifel Nicolaus reduced their target price on shares of Becton, Dickinson and Company from $224.00 to $210.00 in a research note on Friday, November 7th. Three equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $203.27.

Insider Activity

In related news, Director Bertram L. Scott sold 217 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the transaction, the director directly owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. This represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 1,249 shares of company stock worth $231,358 in the last quarter. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $194.00 on Friday. Becton, Dickinson and Company has a 12 month low of $162.29 and a 12 month high of $251.99. The company’s fifty day simple moving average is $187.49 and its 200-day simple moving average is $183.14. The firm has a market cap of $55.37 billion, a PE ratio of 34.89, a P/E/G ratio of 1.42 and a beta of 0.25. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.32 billion during the quarter. Equities research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 31st. Investors of record on Monday, December 8th will be given a $1.05 dividend. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 72.04%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.